Accentia Biopharmaceuticals, Inc. (Accentia) is a biopharmaceutical company focused on the development and commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease and oncology. The Company operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products with an emphasis on the respiratory and oncology therapeutic areas. The products developed in this segment are SinuNase, BiovaxID and Revimmune. This segment also includes the Company’s consulting business, which provides a range of services relating to biopharmaceutical product development, and its biologics products business. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by its third-party development partners. In this segment, Accentia sells the Respi~TANN, SinuTest and Zinotic.

NanoBio is trying to put its NanoStat antimicrobial nanoemulsion technology to work enabling drugs that treat topical and mucosal diseases. The firm's nanoemulsions are formulated to destroy such bacteria as "E. coli", as well as fungi, spores, and viral invaders. NanoBio's two lead candidates are in development to treat cold sores and nail fungus. Other candidates target acne, genital herpes, herpes zoster (better known as shingles), drug-resistant bacterial infections, and viral respiratory infections. NanoBio is also exploring how to use its technology to develop vaccines for hepatitis B and influenza.

Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

Cambridge Laboratories Limited company was founded in 1987 and is now owned by its board of directors. Cambridge Laboratories develops and distributes pharmaceuticals to treat the central nervous system, cancer, vitamin deficiency, and other niches. Its product line includes ImmuCyst (for treatment of superficial bladder cancer), Nabilone (chemotherapy-related nausea and vomiting), and Gelclair (oral ulcers and inflammation). Cambridge Labs has distribution alliances to market its products in over 40 countries.

Acusphere, Inc. is a specialty pharmaceutical company that develops drugs and formulations of existing drugs using its porous microparticle technology. This technology enables the Company to control the size and porosity of particles, including nanoparticles and microparticles, so that the particles can be customized to address the delivery needs of a variety of drugs. These product candidates include Imagify (perflubutane polymer microspheres for delivery in an injectable suspension, formerly known as AI-700), a cardiovascular drug for the detection of coronary artery disease; Hydrophobic Drug Delivery System (HDDS), which converts drugs that do not dissolve well in water into microparticles or nanoparticles of the drugs embedded in small microparticles; and Pulmonary Drug Delivery System (PDDS).

Bayer HealthCare Animal Health Division has Fido and Bessie's wellness in mind. The company is part of the health care division of global chemical and pharmaceutical giant Bayer. The Animal Health Division manufactures anti-infectives, insecticides, parasiticides, sedatives, nutritional supplements, vaccines, and other pharmaceuticals for companion (dogs, cats, horses) and farm (cattle, pigs, poultry, bees) animals. Major products include flea and heartworm treatment Advantage and anti-infective Baytril. The division operates more than 50 branch locations worldwide and sells its products in some 120 countries.

PureTek Corporation company, founded in 1991 by CEO Barry Pressman, manufactures a variety of bulk and private label pharmaceutical, nutritional, and personal care products for retail chain stores and branded drug companies throughout the US. PureTek's nutritional and pharmaceutical products are offered through its Breath Relief, D-CARE, PharmaPure, and Pharmaflex brands. Its personal care items are supplied through the Dermectin and Body Essence lines. PureTek has the ability to produce pharmaceutical and nutritional delivery systems encompassing tablets, capsules and liquids, as well as large-batch capacity for personal care liquids, lotions, creams, and oils.

Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company develops Zemiva, a molecular imaging pharmaceutical product, which completed Phase II clinical trail for the diagnosis of cardiac ischemia or insufficient blood flow to the heart; and Trofex, a preclinical trail product for the detection of metastatic prostate cancer. Its molecular radiotherapeutic oncology product candidates under development include Azedra that completed Phase I clinical trail for the treatment of pheochromocytoma in adults and neuroblastoma in children; Onalta, a Phase II clinical trail product for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors; and Solazed, a preclinical trail product for the treatment of malignant metastatic melanoma. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003.

Tengion, Inc., a regenerative medicine company, focuses on discovering, developing, manufacturing, and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. It creates these functional neo-organs and neo-tissues using a patient’s own cells, or autologous cells, in conjunction with the company’s Organ Regeneration Platform. The company’s lead product candidate, the Neo-Urinary Conduit, is an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal, or cystectomy. Its product pipeline also includes various candidates in early stage development, such as Neo-Kidney Augment for patients with advanced chronic kidney disease, or CKD. The company was founded in 2003 and is headquartered in East Norriton, Pennsylvania.

Imperial Ginseng Products company cultivates more than 550 acres of North American ginseng root used in traditional Chinese medicine. The company operates a farm in Ontario, Canada, where the root is grown for three or four years (each year increases yield and value), harvested, and dried. Imperial Ginseng Products sells the dried root to buyers in North America and Asia, who then turn it into prepared remedies. CDS & Co owns 55% of the company, while co-chairmen Hugh Cartwright and Stephen McCoach and director Maurice Levesque together hold nearly 40%.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.